HK1007681A1 - Use of pirenzepine telenzepine oder o-methoxy-sila-hexocyclium in the manufacture of a medicament for the treatment and control of ocular development - Google Patents

Use of pirenzepine telenzepine oder o-methoxy-sila-hexocyclium in the manufacture of a medicament for the treatment and control of ocular development

Info

Publication number
HK1007681A1
HK1007681A1 HK98106920A HK98106920A HK1007681A1 HK 1007681 A1 HK1007681 A1 HK 1007681A1 HK 98106920 A HK98106920 A HK 98106920A HK 98106920 A HK98106920 A HK 98106920A HK 1007681 A1 HK1007681 A1 HK 1007681A1
Authority
HK
Hong Kong
Prior art keywords
hexocyclium
telenzepine
pirenzepine
sila
methoxy
Prior art date
Application number
HK98106920A
Other languages
English (en)
Inventor
Richard A Stone
Alan M Laties
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/522,241 external-priority patent/US5122522A/en
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of HK1007681A1 publication Critical patent/HK1007681A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK98106920A 1989-06-21 1998-06-26 Use of pirenzepine telenzepine oder o-methoxy-sila-hexocyclium in the manufacture of a medicament for the treatment and control of ocular development HK1007681A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36929389A 1989-06-21 1989-06-21
US07/522,241 US5122522A (en) 1989-06-21 1990-05-11 Treatment and control of ocular development
PCT/US1990/003444 WO1990015604A1 (en) 1989-06-21 1990-06-14 Treatment and control of ocular development

Publications (1)

Publication Number Publication Date
HK1007681A1 true HK1007681A1 (en) 1999-04-23

Family

ID=27004525

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98106920A HK1007681A1 (en) 1989-06-21 1998-06-26 Use of pirenzepine telenzepine oder o-methoxy-sila-hexocyclium in the manufacture of a medicament for the treatment and control of ocular development

Country Status (10)

Country Link
US (2) US5356892A (xx)
EP (1) EP0478694B1 (xx)
JP (4) JP3165436B2 (xx)
AT (3) ATE147626T1 (xx)
CA (1) CA2058768C (xx)
DE (3) DE69029734T2 (xx)
DK (1) DK0737475T3 (xx)
ES (2) ES2159661T3 (xx)
HK (1) HK1007681A1 (xx)
WO (1) WO1990015604A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
JP3165436B2 (ja) * 1989-06-21 2001-05-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 眼の発達の治療及び制御
WO1993013777A1 (en) * 1992-01-21 1993-07-22 Merck & Co., Inc. Method of using m1-selective antimuscarinic pyridobenzodiazepinones in axial myopia therapy
US5716952A (en) * 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth
US5756508A (en) * 1995-10-31 1998-05-26 Merck & Co., Inc. Muscarine antagonists
WO1998030900A2 (en) * 1997-01-06 1998-07-16 Klaus Trier Aps Screening method for compounds active in treating myopia and hypermetropia
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
MXPA02007039A (es) * 2000-01-18 2003-09-25 Univ Pennsylvania Crecimiento ocular y antagonistas nicotinicos.
RU2297831C2 (ru) * 2001-05-25 2007-04-27 Валлей Форге Фармацевтикалс Инк. Офтальмологический гель пирензепина
ITUB20160876A1 (it) 2016-02-19 2017-08-19 Dambrosio Enzo Maria Combinazione di un agente antiallergico con un antagonista muscarinico e/o un agonista dopaminergico per l'uso in prevenzione/ arresto di miopia assiale nell’uomo

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU188852B (en) * 1983-03-16 1986-05-28 Richter Gedeon Vegyeszeti Gyar Rt,Hu Process for producing thiazolidine derivatives active against gastric ulcer and intestinal ulcer
US4865599A (en) * 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
US5122522A (en) * 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
JP3165436B2 (ja) * 1989-06-21 2001-05-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 眼の発達の治療及び制御
US5360801A (en) * 1989-06-21 1994-11-01 The Trustees Of The University Of Pennsylvania Pharmacological stimulation of eye growth
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth

Also Published As

Publication number Publication date
CA2058768C (en) 2004-08-03
CA2058768A1 (en) 1990-12-22
DE69033775D1 (de) 2001-09-06
JP2004075695A (ja) 2004-03-11
JP3461778B2 (ja) 2003-10-27
ATE203666T1 (de) 2001-08-15
ES2136686T3 (es) 1999-12-01
ATE147626T1 (de) 1997-02-15
ES2159661T3 (es) 2001-10-16
EP0478694B1 (en) 1997-01-15
DE69033775T2 (de) 2001-11-15
JP2001081046A (ja) 2001-03-27
EP0478694A1 (en) 1992-04-08
JP2000204049A (ja) 2000-07-25
WO1990015604A1 (en) 1990-12-27
US5356892A (en) 1994-10-18
DK0737475T3 (da) 2001-10-08
ATE183085T1 (de) 1999-08-15
DE69033246D1 (de) 1999-09-16
DE69029734D1 (de) 1997-02-27
JPH05500502A (ja) 1993-02-04
DE69033246T2 (de) 1999-12-02
EP0478694A4 (en) 1992-07-29
DE69029734T2 (de) 1997-05-28
US5637604A (en) 1997-06-10
JP3165436B2 (ja) 2001-05-14

Similar Documents

Publication Publication Date Title
US6410544B1 (en) Cholinergic agents in the treatment of presbyopia
HK1007681A1 (en) Use of pirenzepine telenzepine oder o-methoxy-sila-hexocyclium in the manufacture of a medicament for the treatment and control of ocular development
EP0348360A3 (en) Pharmacological use of uridine in the treatment of nervous disorders
KR920702622A (ko) 안구 발육의 치료 및 조절
HK1007680A1 (en) Pharmacological treatment of ocular development
JPH08511024A (ja) 眼内圧を低下させる方法および組成物
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
KEITNER et al. Spontaneous ejaculations and neuroleptics
UA41329C2 (uk) Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, похідні 3-фенілсульфоніл-3,7-діазабіцикло[3,3,1]нонану та лікарський засіб для лікування аритмії
JPS6483020A (en) Medicinal composition for preventing or treating aids
CA2369054A1 (en) Treatment and control of ocular development
HK1015692A1 (en) Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8, for treating infections
Hurwitz et al. The effects of the sympathetic nervous system on accommodation: II. Alpha sympathetic nervous system
ES473461A1 (es) Un procedimiento para la preparacion de dibenzo (a,d) ci- cloocten-5,12 (6,12)-iminas y sus derivados
JPS6461425A (en) Improvement for cyclosporin remedy
JPS6426518A (en) Remedy for hyperophthalmotony
Moore et al. Effects of N, N-dimethyltryptamine on electrically evoked responses in the cat visual system and modification by neuroleptic agents
Dunagan et al. Nerves originating from the cerebral ganglion of Moniliformis moniliformis (Acanthocephala)
Vickers The forgotten dysfunction: a pharmacological approach to premature ejaculation
Flentje et al. Diurnal variations of tumor growth and its influence on cytostatic treatment
JPS5572193A (en) 9*100dihydroo4hhbenzo*4*5*cycloheptaa *1*22b*thiophenee4*99imine
MacDonnell et al. Disulfiram and brain-stimulated emotional behavior
Pagni et al. Therapeutic program in cancer pain: Minerva med., 72 (1981) 1–16
UA20026A (uk) Спосіб профілактики та лікуваhhя катаракти
Chang Transient neurogenic bladder in genital herpes

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080614